LOWERING DRUG COSTS — Bipartisan lawmakers have revived efforts to require Medicare to cover generic drugs — and at least two biosimilars — with patients paying lower costs than for brand-name drugs, ...

Multiple dapagliflozin generic approvals are expected to intensify near-term market competition, requiring manufacturers to coordinate production readiness, launch timing, and labeling compliance ...

https://www.thehindubusinessline.com/companies/generic-versions-of-novo-nordisks-semaglutide-begin-to-flow-priced-50-80-lower-than-the-innovator/article70769849.ece ...

The simultaneous patent expiry of Ozempic’s active ingredient in China and India on Friday is a watershed moment. Until now, the revolutionary weight-loss drugs have been available largely to people ...

The upcoming expiry of the semaglutide patent in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the ...

If you've felt nostalgic for some older Marvel games lately, the 'Maximum Collection' is here to meet your retro needs. Reading time 1 minute As Marvel gears up for some new video games with Marvel ...

Learn to crochet a love letter collection including a bag, wallet/envelope, and book sleeve with these beginner-friendly tutorials. #CrochetTutorials #LoveLetterCollection #BeginnerCrochet Exotic ...

COLORADO, CO, UNITED STATES, January 20, 2026 /EINPresswire.com/ — Vibrant Publishers is thrilled to announce the release of Java Essentials Volume 2: Object ...

TORONTO — Novo Nordisk Canada is considering competing with generic versions of its brand-name Ozempic and Wegovy drugs by introducing renamed, lower-priced copies of the medications. Health Canada ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...